Stock LALPATHLAB DR. LAL PATHLABS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dr. Lal PathLabs Limited Bombay S.E.

Equities

LALPATHLAB

INE600L01024

Healthcare Facilities & Services

Delayed Bombay S.E.
Other stock markets
 06:00:49 2024-04-29 am EDT 		5-day change 1st Jan Change
2,349 INR -1.60% Intraday chart for Dr. Lal PathLabs Limited +3.83% -8.59%
Apr. 26 Dr. Lal Pathlabs Limited Announces Resignation of Bharath U as Chief Executive Officer, Effective May 9, 2024 CI
Mar. 18 Dr Lal Pathlabs Names CEO MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 87,034 115,422 223,265 215,706 151,339 198,354 - -
Enterprise Value (EV) 1 80,283 108,088 213,412 212,332 145,552 190,629 187,368 183,570
P/E ratio 43.2 x 51.2 x 76.8 x 62.8 x 63.6 x 55.8 x 48 x 41.3 x
Yield 0.57% 0.86% 0.52% 0.46% 0.66% 0.72% 0.77% 0.88%
Capitalization / Revenue 7.23 x 8.68 x 14.1 x 10.3 x 7.5 x 8.87 x 7.95 x 7.13 x
EV / Revenue 6.67 x 8.12 x 13.5 x 10.2 x 7.22 x 8.53 x 7.51 x 6.6 x
EV / EBITDA 27.3 x 31.5 x 48.9 x 37.9 x 29.7 x 31.3 x 27.7 x 24.2 x
EV / FCF 43.7 x 45.6 x 58.9 x 60.2 x 34.7 x 45 x 36.9 x 32.1 x
FCF Yield 2.29% 2.19% 1.7% 1.66% 2.88% 2.22% 2.71% 3.12%
Price to Book 9.11 x 11.3 x 18.1 x 14.4 x 9.15 x 10.6 x 9.38 x 8.27 x
Nbr of stocks (in thousands) 83,342 82,344 82,475 82,624 82,785 83,051 - -
Reference price 2 1,044 1,402 2,707 2,611 1,828 2,388 2,388 2,388
Announcement Date 5/17/19 5/18/20 5/21/21 5/17/22 5/11/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 12,034 13,304 15,813 20,874 20,169 22,359 24,939 27,823
EBITDA 1 2,936 3,436 4,363 5,607 4,899 6,091 6,754 7,579
EBIT 1 2,554 2,708 3,591 4,526 3,397 4,651 5,220 5,969
Operating Margin 21.22% 20.35% 22.71% 21.68% 16.84% 20.8% 20.93% 21.45%
Earnings before Tax (EBT) 1 3,006 3,105 3,944 4,749 3,439 5,014 5,743 6,655
Net income 1 2,005 2,276 2,916 3,448 2,389 3,569 4,159 4,827
Net margin 16.66% 17.11% 18.44% 16.52% 11.84% 15.96% 16.68% 17.35%
EPS 2 24.15 27.37 35.25 41.57 28.74 42.78 49.80 57.82
Free Cash Flow 1 1,837 2,368 3,626 3,526 4,195 4,238 5,074 5,719
FCF margin 15.26% 17.8% 22.93% 16.89% 20.8% 18.96% 20.35% 20.55%
FCF Conversion (EBITDA) 62.57% 68.92% 83.1% 62.88% 85.63% 69.59% 75.14% 75.46%
FCF Conversion (Net income) 91.62% 104.04% 124.34% 102.26% 175.6% 118.76% 122.02% 118.47%
Dividend per Share 2 6.000 12.00 14.00 12.00 12.00 17.23 18.41 21.04
Announcement Date 5/17/19 5/18/20 5/21/21 5/17/22 5/11/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 4,524 4,310 6,066 4,984 4,969 4,855 5,027 5,338 4,894 4,910 5,410 5,898 5,588 5,459 6,029
EBITDA 1 1,388 1,220 1,890 1,415 1,092 1,211 1,175 1,438 1,130 1,156 1,462 1,600 1,468 1,399 -
EBIT 1 1,193 1,017 1,844 1,210 785 834 816 1,050 751 780 1,111 1,288 1,083 1,077 1,217
Operating Margin 26.37% 23.6% 30.4% 24.28% 15.8% 17.18% 16.23% 19.67% 15.35% 15.89% 20.54% 21.83% 19.38% 19.73% 20.19%
Earnings before Tax (EBT) 1 1,289 1,108 1,793 1,306 815 835 814 1,028 765 832 1,175 1,335 1,200 1,099 -
Net income 1 945 834 1,312 950 573 613 577 717 528 567 826 928.4 855.3 810.8 -
Net margin 20.89% 19.35% 21.63% 19.06% 11.53% 12.63% 11.48% 13.43% 10.79% 11.55% 15.27% 15.74% 15.31% 14.85% -
EPS 2 11.41 10.07 15.84 11.45 6.900 7.380 6.960 8.600 6.350 6.820 9.930 11.51 10.32 9.749 -
Dividend per Share 2 - 8.000 - - - - - - - 12.00 - - - 10.20 -
Announcement Date 1/29/21 5/21/21 7/30/21 10/26/21 2/10/22 5/17/22 7/28/22 11/8/22 2/2/23 5/11/23 7/27/23 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 6,751 7,334 9,853 3,374 5,787 7,725 10,986 14,784
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 1,837 2,368 3,626 3,526 4,195 4,238 5,075 5,719
ROE (net income / shareholders' equity) 23.1% 23% 25.6% 25.1% 15.1% 19.9% 20.4% 20.8%
ROA (Net income/ Total Assets) 20% 18.5% 19.2% 17.2% 10.1% 13.6% 14.8% 16%
Assets 1 10,031 12,324 15,178 20,071 23,661 26,242 28,101 30,171
Book Value Per Share 2 115.0 124.0 149.0 181.0 200.0 225.0 255.0 289.0
Cash Flow per Share 2 26.20 34.10 48.10 53.90 54.70 55.20 65.60 74.20
Capex 1 348 471 356 941 365 586 606 607
Capex / Sales 2.9% 3.54% 2.25% 4.51% 1.81% 2.62% 2.43% 2.18%
Announcement Date 5/17/19 5/18/20 5/21/21 5/17/22 5/11/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Dr. Lal PathLabs Limited

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
2,388 INR
Average target price
2,455 INR
Spread / Average Target
+2.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

1st Jan change Capi.
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-16.58% 8.25B
RADNET, INC. Stock RadNet, Inc.
+39.20% 3.58B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
-39.11% 2.46B
SYNLAB AG Stock SYNLAB AG
-8.41% 2.46B
FLEURY S.A. Stock Fleury S.A.
-19.01% 1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD. Stock Dian Diagnostics Group Co.,Ltd.
-40.66% 1.21B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
+7.56% 1.11B
ADICON HOLDINGS LIMITED Stock Adicon Holdings Limited
-15.03% 1.03B
OPKO HEALTH, INC. Stock OPKO Health, Inc.
-16.56% 878M
Medical & Diagnostic Laboratories
  1. Stock Market
  2. Equities
  3. LALPATHLAB Stock
  4. LALPATHLAB Stock
  5. Financials Dr. Lal PathLabs Limited